TABLE 1.
Characteristics of the five KT recipients with COVID‐19 infection a
| Median age (minimum, maximum) | 13 years (7–16 years) |
| Gender, n (%) | Female: 4 (80%) |
| Type of transplant, n (%) | Deceased‐donor transplant: 5 (100%) |
| Underlying kidney disease, n (%) | Steroid‐resistant nephrotic syndrome: 2 (40%) |
| Renal tubular dysgenesis: 1 (20%) | |
| Nephronophthisis: 1 (20%) | |
| Unknown: 1 (20%) | |
| Comorbidities, n (%) | Hypertension: 5 (100%) |
| Hyperuricemia: 2 (40%) | |
| Left ventricular hypertrophy: 1 (20%) | |
| Patent arterial duct surgically treated: 1 (20%) | |
| Mild aortic regurgitation: 1 (20%) | |
| Baseline immunosuppression, n (%) | Glucocorticoids, mycophenolate mofetil and tacrolimus: 5 (100%) |
| Median time after KT at COVID‐19 diagnosis (minimum, maximum) | 38 months (1 month‐11 years) |
| Median follow‐up after COVID‐19 (minimum, maximum) | 2 months (2–9 months) |
| Signs and symptoms, n (%) | Fever: 2 (40%) |
| Cough: 2 (40%) | |
| Rhinorrhoea: 2 (40%) | |
| Myalgias: 2 (40%) | |
| Headache: 2 (40%) | |
| Sore throat: 1 (20%) | |
| Diarrhoea: 1 (20%) | |
| Anosmia: 1 (20%) | |
| Asymptomatic: 1 (20%) | |
| Laboratory findings, n (%) | Lymphopenia (<1000/mcL): 2 (40%) |
| Thrombocytopenia (<150.000/mcL): 1 (20%) | |
| Median eGFR in ml/min/1.73 m2 (minimum, maximum) | Baseline eGFR: 102.6 (63.2–212.8) |
| eGFR at COVID‐19 diagnosis: 99.1 (48.8–174.8) | |
| Allograft outcome, n (%) | Acute dysfunction: 2 (40%) |
| Graft loss: 0 (0%) | |
| Hospital admission, n (%) | None (0%) |
| COVID‐19 infection treatment, n (%) | Supportive treatment only: 5 (100%) |
| Other: none (0%) | |
| COVID‐19 total antibody response, n (%) | 5 (100%) |
a
All COVID‐19 cases were identified by a polymerase chain reaction test for SARS‐CoV‐2 in nasal and oropharyngeal swab.